Pathology and Toxicology yConsultancy. Supporting Early Discovery - exposure models benchmarked to relevant hazard endpoints - aiding molecule selection. The use of surrogate systems to support chemistry designBiopharma target identification - ISH and IHCRegulatory toxicology Studies - all stages of the development programme.Product Life Cycle Management - including MoA exploration and Non Human Relevance Frameworks. Research Projects - to explore and understand carcinogenesis, developmental anomalies, target organ toxicity etcRetrospective evaluation of FFPE tissue from existing studies - IHC, ISH (RNA scope), Image Analysis, microarrays etc

Early Discovery - developing testing strategies to aid compoound selection and the Design Synthesis test analysis cycle. Incluidng exploring the utility of surrogate systems - in vitro and lower organismsSupport (tox and path) for development compounds through the regulatory hurdles, including MoA work for the non human relevance framework. In situ hybridisation (mRNA and miRNA) and microarrays using FFPE (laser dissection), dual localisation of expressed proteins. Bespoke studies to support MoA hypotheses Research projects to explore and understand carcinogenesis, developmental anomalies, dermal absorption, target organ toxicity.